IFNG and non-small cell lung carcinoma: In addition, in NSCLC patients receiving durvalumab, those with a four-gene IFNγ-positive (IFNγ +) signature, namely IFNγ, CD274, LAG3, and CXCL9, showed greater ORR and longer median OS and PFS, irrespective of their PD-L1 status [59].